In preclinical studies, CDK4/6 inhibitor, palbociclib, had an additive effect on cell death in pancreatic ductal carcinoma cell lines when combined with MEK or PI3K/mTOR inhibitors [40]. This evidence concerns the gene MTOR and pancreatic ductal adenocarcinoma.